A survey of 175 pharma executives highlights an increasing reluctance to launch in lower-value markets, alongside a ...

Steven Paul’s “How to improve R&D productivity: the pharmaceutical industry's grand challenge” published in Nature Reviews Drug Discovery in 2010 is one of the highest cited and most frequently quoted ...

Forbes contributors publish independent expert analyses and insights. Expert in AI for healthcare and longevity biotechnology Sep 27, 2023, 12:53pm EDT This article is more than 2 years old. The ...

Pharma’s return on investment (ROI) for research and development (R&D) is seeing a comeback after a record low in 2022, according to a recent report out of Deloitte. ROI on pharma R&D jumped to 4.1% ...

While coming back down from 2023’s dizzying high, Merck & Co. still managed to hang on to the top spot of our annual R&D budgets in pharma list. Though Merck’s 2024 R&D spending plummeted by almost ...

After years of declining returns, pharmaceutical research and development is showing signs of sustained recovery. According to a Deloitte report, the internal rate of return for the top 20 biopharma ...

Another R&D budget ranking has arrived, and Roche remains the top dog among the world’s largest pharmaceutical companies. Roche spent 14.05 billion Swiss francs on R&D in 2022, or roughly $15.15 ...